Studies of HCT116 cells xenografts in the nude mouse model also indicated that NDAT, alone and in combination with gefitinib, reduced PI3K activity, total amount of ST6Gal1 protein, and tumor size compared to single agent gefitinib-treated tumor (Fig. 7). Here, ST6GAL1 is linked to neoplasm.